Symptoms of overdose include somnolence, confusion, coma, and diminished reflexes. Respiration, pulse and blood pressure should be monitored.
Prazepam is a benzodiazepine that is used in the treatment of anxiety disorders. It is a schedule IV drug in the U.S.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Buprenorphine | Prazepam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Prazepam. |
| Dronabinol | Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Prazepam. |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of Prazepam. |
| Hydrocodone | Prazepam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. |
| Hydroxyzine | Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Prazepam. |
| Magnesium sulfate | The therapeutic efficacy of Prazepam can be increased when used in combination with Magnesium sulfate. |
| Methotrimeprazine | Prazepam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. |
| Metyrosine | Prazepam may increase the sedative activities of Metyrosine. |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of Prazepam. |
| Mirtazapine | Prazepam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine. |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of Prazepam. |
| Orphenadrine | Prazepam may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. |
| Paraldehyde | Prazepam may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. |
| Perampanel | Perampanel may increase the central nervous system depressant (CNS depressant) activities of Prazepam. |
| Pramipexole | Prazepam may increase the sedative activities of Pramipexole. |
| Ropinirole | Prazepam may increase the sedative activities of Ropinirole. |
| Rotigotine | Prazepam may increase the sedative activities of Rotigotine. |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with Prazepam. |
| Suvorexant | Prazepam may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
| Tapentadol | Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Prazepam. |
| Thalidomide | Prazepam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. |
| Zolpidem | Prazepam may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. |
| Clozapine | The risk or severity of adverse effects can be increased when Prazepam is combined with Clozapine. |
| Methadone | Prazepam may increase the central nervous system depressant (CNS depressant) activities of Methadone. |
| Sodium oxybate | Prazepam may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate. |
| Teduglutide | The serum concentration of Prazepam can be increased when it is combined with Teduglutide. |
| Yohimbine | The therapeutic efficacy of Prazepam can be increased when used in combination with Yohimbine. |
| Ethanol | Prazepam may increase the central nervous system depressant (CNS depressant) activities of Ethanol. |
| Azelastine | Prazepam may increase the central nervous system depressant (CNS depressant) activities of Azelastine. |
| Brimonidine | Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Prazepam. |
| Zimelidine | The risk or severity of adverse effects can be increased when Prazepam is combined with Zimelidine. |
| Dapoxetine | The risk or severity of adverse effects can be increased when Prazepam is combined with Dapoxetine. |
| Seproxetine | The risk or severity of adverse effects can be increased when Prazepam is combined with Seproxetine. |
| Fluvoxamine | The risk or severity of adverse effects can be increased when Prazepam is combined with Fluvoxamine. |
| Citalopram | The risk or severity of adverse effects can be increased when Prazepam is combined with Citalopram. |
| Duloxetine | The risk or severity of adverse effects can be increased when Prazepam is combined with Duloxetine. |
| Trazodone | The risk or severity of adverse effects can be increased when Prazepam is combined with Trazodone. |
| Paroxetine | The risk or severity of adverse effects can be increased when Prazepam is combined with Paroxetine. |
| Sertraline | The risk or severity of adverse effects can be increased when Prazepam is combined with Sertraline. |
| Sibutramine | The risk or severity of adverse effects can be increased when Prazepam is combined with Sibutramine. |
| Escitalopram | The risk or severity of adverse effects can be increased when Prazepam is combined with Escitalopram. |
| Milnacipran | The risk or severity of adverse effects can be increased when Prazepam is combined with Milnacipran. |
| Desvenlafaxine | The risk or severity of adverse effects can be increased when Prazepam is combined with Desvenlafaxine. |
| Levomilnacipran | The risk or severity of adverse effects can be increased when Prazepam is combined with Levomilnacipran. |
| Indalpine | The risk or severity of adverse effects can be increased when Prazepam is combined with Indalpine. |
| Ritanserin | The risk or severity of adverse effects can be increased when Prazepam is combined with Ritanserin. |
| Alaproclate | The risk or severity of adverse effects can be increased when Prazepam is combined with Alaproclate. |
| Cyproheptadine | The risk or severity of CNS depression can be increased when Cyproheptadine is combined with Prazepam. |
| Propiomazine | The risk or severity of CNS depression can be increased when Propiomazine is combined with Prazepam. |
| Nicardipine | The metabolism of Prazepam can be decreased when combined with Nicardipine. |
| Olanzapine | The risk or severity of CNS depression can be increased when Olanzapine is combined with Prazepam. |
| Zopiclone | The risk or severity of adverse effects can be increased when Prazepam is combined with Zopiclone. |
| Caffeine | The therapeutic efficacy of Prazepam can be decreased when used in combination with Caffeine. |
| Dyphylline | The therapeutic efficacy of Prazepam can be decreased when used in combination with Dyphylline. |
| Pentoxifylline | The therapeutic efficacy of Prazepam can be decreased when used in combination with Pentoxifylline. |
| Mercaptopurine | The therapeutic efficacy of Prazepam can be decreased when used in combination with Mercaptopurine. |
| Oxtriphylline | The therapeutic efficacy of Prazepam can be decreased when used in combination with Oxtriphylline. |
| Theobromine | The therapeutic efficacy of Prazepam can be decreased when used in combination with Theobromine. |
| Fenethylline | The therapeutic efficacy of Prazepam can be decreased when used in combination with Fenethylline. |
| 8-azaguanine | The therapeutic efficacy of Prazepam can be decreased when used in combination with 8-azaguanine. |
| 7,9-Dimethylguanine | The therapeutic efficacy of Prazepam can be decreased when used in combination with 7,9-Dimethylguanine. |
| Xanthine | The therapeutic efficacy of Prazepam can be decreased when used in combination with Xanthine. |
| 7-Deazaguanine | The therapeutic efficacy of Prazepam can be decreased when used in combination with 7-Deazaguanine. |
| Guanine | The therapeutic efficacy of Prazepam can be decreased when used in combination with Guanine. |
| 9-Methylguanine | The therapeutic efficacy of Prazepam can be decreased when used in combination with 9-Methylguanine. |
| Peldesine | The therapeutic efficacy of Prazepam can be decreased when used in combination with Peldesine. |
| Hypoxanthine | The therapeutic efficacy of Prazepam can be decreased when used in combination with Hypoxanthine. |
| 9-Deazaguanine | The therapeutic efficacy of Prazepam can be decreased when used in combination with 9-Deazaguanine. |
| Propentofylline | The therapeutic efficacy of Prazepam can be decreased when used in combination with Propentofylline. |
| Valomaciclovir | The therapeutic efficacy of Prazepam can be decreased when used in combination with Valomaciclovir. |
| 3-isobutyl-1-methyl-7H-xanthine | The therapeutic efficacy of Prazepam can be decreased when used in combination with 3-isobutyl-1-methyl-7H-xanthine. |
| Uric acid | The therapeutic efficacy of Prazepam can be decreased when used in combination with Uric acid. |
| Doxofylline | The therapeutic efficacy of Prazepam can be decreased when used in combination with Doxofylline. |
| 6-O-benzylguanine | The therapeutic efficacy of Prazepam can be decreased when used in combination with 6-O-benzylguanine. |
| Lisofylline | The therapeutic efficacy of Prazepam can be decreased when used in combination with Lisofylline. |
| Lobucavir | The therapeutic efficacy of Prazepam can be decreased when used in combination with Lobucavir. |
| Cafedrine | The therapeutic efficacy of Prazepam can be decreased when used in combination with Cafedrine. |
| Theodrenaline | The therapeutic efficacy of Prazepam can be decreased when used in combination with Theodrenaline. |
| Bamifylline | The therapeutic efficacy of Prazepam can be decreased when used in combination with Bamifylline. |
| Proxyphylline | The therapeutic efficacy of Prazepam can be decreased when used in combination with Proxyphylline. |
| Acefylline | The therapeutic efficacy of Prazepam can be decreased when used in combination with Acefylline. |
| Etamiphylline | The therapeutic efficacy of Prazepam can be decreased when used in combination with Etamiphylline. |
| Pentifylline | The therapeutic efficacy of Prazepam can be decreased when used in combination with Pentifylline. |
| Bufylline | The therapeutic efficacy of Prazepam can be decreased when used in combination with Bufylline. |
| Bromotheophylline | The therapeutic efficacy of Prazepam can be decreased when used in combination with Bromotheophylline. |
| Furafylline | The therapeutic efficacy of Prazepam can be decreased when used in combination with Furafylline. |
| 8-chlorotheophylline | The therapeutic efficacy of Prazepam can be decreased when used in combination with 8-chlorotheophylline. |
| PCS-499 | The therapeutic efficacy of Prazepam can be decreased when used in combination with PCS-499. |
| Theophylline | The therapeutic efficacy of Prazepam can be decreased when used in combination with Theophylline. |
| Aminophylline | The therapeutic efficacy of Prazepam can be decreased when used in combination with Aminophylline. |
| Botulinum toxin type B | The risk or severity of CNS depression can be increased when Botulinum toxin type B is combined with Prazepam. |
| Botulinum toxin type A | The risk or severity of CNS depression can be increased when Botulinum toxin type A is combined with Prazepam. |
| Baclofen | Baclofen may increase the central nervous system depressant (CNS depressant) activities of Prazepam. |
| Ethchlorvynol | The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with Prazepam. |
| Succinylcholine | The risk or severity of CNS depression can be increased when Succinylcholine is combined with Prazepam. |
| Enflurane | The risk or severity of CNS depression can be increased when Enflurane is combined with Prazepam. |
| Butabarbital | The risk or severity of CNS depression can be increased when Butabarbital is combined with Prazepam. |
| Butalbital | The risk or severity of CNS depression can be increased when Butalbital is combined with Prazepam. |
| Cabergoline | The risk or severity of CNS depression can be increased when Cabergoline is combined with Prazepam. |